ReviewFuture microbiology2019
Sarecycline: a narrow spectrum tetracycline for the treatment of moderate-to-severe acne vulgaris.
Review in Future microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Sarecycline for moderate to severe acne: a promising narrow-spectrum antibacterial drug.Naunyn-Schmiedeberg's archives of pharmacology · 2025Pooled it
- A Comprehensive Review of Acne Treatments: Unpacking the Chemical Structures and Effective Bioactive Compounds.Health science reports · 2026Article
- Optimal Use Recommendations and Stewardship Principles with Oral Antibiotics in Acne Vulgaris Management: An Expert Consensus Panel.The Journal of clinical and aesthetic dermatology · 2025Review
- Efficacy and Safety of Sarecycline in Chinese Patients with Moderate-to-Severe Acne Vulgaris: Randomized Phase 3 Clinical Trial with Open-Label Follow-Up.Dermatology and therapy · 2025Article
- Article
- Exploring Acne Treatments: From Pathophysiological Mechanisms to Emerging Therapies.International journal of molecular sciences · 2024Review
- Tetracyclines Revisited: Tetracyclines in the Field of Dermatology.Dermatology (Basel, Switzerland) · 2024Review
- Bidirectional Interaction between Tetracyclines and Gut Microbiome.Antibiotics (Basel, Switzerland) · 2023Review
- Article
- Antibiotics and Antimicrobial Resistance in Acne: Epidemiological Trends and Clinical Practice Considerations.The Yale journal of biology and medicine · 2022Review
- Antibiotic Resistance Risk with Oral Tetracycline Treatment of Acne Vulgaris.Antibiotics (Basel, Switzerland) · 2022Article
- Profiling the Effects of Systemic Antibiotics for Acne, Including the Narrow-Spectrum Antibiotic Sarecycline, on the Human Gut Microbiota.Frontiers in microbiology · 2022Article
- The Development of Third-Generation Tetracycline Antibiotics and New Perspectives.Pharmaceutics · 2021Review
- Tetracyclines and photosensitive skin reactions: A narrative review.Dermatologic therapy · 2021Review
- New Acne Therapies and Updates on Use of Spironolactone and Isotretinoin: A Narrative Review.Dermatology and therapy · 2021Review
- Development and Research Progress of Anti-Drug Resistant Bacteria Drugs.Infection and drug resistance · 2021Review
- SARECYCLINE AND THE NARROW-SPECTRUM TETRACYCLINE CONCEPT: Currently Available Data and Potential Clinical Relevance in Dermatology.The Journal of clinical and aesthetic dermatology · 2020Review
- Antibiotics in the clinical pipeline in October 2019.The Journal of antibiotics · 2020Review
- Sarecycline: A Review of Preclinical and Clinical Evidence.Clinical, cosmetic and investigational dermatology · 2020Review
- FDA approved antibacterial drugs: 2018-2019.Discoveries (Craiova, Romania) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarecycline is a novel, narrow-spectrum, once-daily tetracycline-derived oral antibiotic that is FDA-approved in the US to be taken with or without food for moderate-to-severe acne vulgaris for ages 9 years of age and older. Sarecycline possesses anti-inflammatory properties and potent activity against Gram-positive bacteria, including activity against multiple strains of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.